Introduction {#section5-1179546817747258}
============

Tyrosine kinase inhibitors (TKIs) are standard therapy in chronic myeloid leukemia (CML) individuals, especially for second-generation TKIs, and these inhibitors include nilotinib and dasatinib which pursue more cytogenetic and molecular response compared with imatinib.^[@bibr1-1179546817747258][@bibr2-1179546817747258][@bibr3-1179546817747258][@bibr4-1179546817747258]--[@bibr5-1179546817747258]^ Although the efficacy of newer TKIs has been proved, the association of TKIs with long-term complications has been of concern. There were a few studies among nilotinib-receiving patients who experienced peripheral artery occlusive disease (PAOD) and cardiovascular diseases.^[@bibr6-1179546817747258],[@bibr7-1179546817747258]^ Most of these were case reports and case series. Atherosclerotic risk modifications are essential for the prevention of these complications, and some of them require angioplasty. Nilotinib increases the risk of PAOD more than imatinib by 14.6 times, and a 10-year probability of being free from PAOD for imatinib and nilotinib was found to be 100% and 67%, respectively.^[@bibr8-1179546817747258]^ However, these studies had a small scale of population and lack of metabolic profiles and ankle-brachial index (ABI) for PAOD screening. Most of the previous studies on PAOD in CML individuals have revealed arterial occlusion to be clinically overt and recommended that the patients who had cardiovascular risk factors, for example, diabetes, hyperlipidemia, and hypertension, be screened for PAOD. This complication also brought about a decline in the quality of life and was related to many comorbidities.

In this study, we performed the cross-sectional case-control study to compare the prevalence of PAOD between patients with CML who were receiving TKIs and non-CML patients. All PAOD-related parameters were collected, and PAOD screening with ABI was performed.

Materials and Methods {#section6-1179546817747258}
=====================

This was a single-center, cross-sectional, case-control study of patients who were diagnosed with CML and were receiving TKIs at Chiang Mai University Hospital between February 2014 and December 2014 in comparison with a control population in a 1:2 ratio with age, sex, and diabetes status matched. The study protocol was approved by the Institutional Review Board of Chiang Mai University and was conducted according to the Declaration of Helsinki. All patients provided written informed consent.

Patients and control population {#section7-1179546817747258}
-------------------------------

All the study participants were adults (age \>18 years) diagnosed with the chronic phase of CML and patients in Chiang Mai University Hospital. The clinical variables and the PAOD-related risk factors were recorded. Both the case and the control groups were screened to obtain ABI with the VaSera VS-1500N instrument (Fukuda Denshi Co Ltd, Tokyo, Japan). Ankle-brachial index values lower than 0.9 were classified into pathologic outcomes.^[@bibr9-1179546817747258]^ In cases of pathologic ABI, duplex ultrasound scan of lower legs or computed tomography angiogram was performed for confirming the diagnosis of PAOD.

Statistical analysis {#section8-1179546817747258}
--------------------

According to previous reports on PAOD prevalence in patients with CML, the prevalence was found to be around 20%,^[@bibr10-1179546817747258],[@bibr11-1179546817747258]^ and for the general population, it reached 5%.^[@bibr12-1179546817747258]^ With the 2-sided significance level of .05 with at least 80% power, the planned sample size for the 1:2 ratio consisted of 76 patients and 152 patients for the case group and the control group, respectively. The subgroups were compared using χ^2^ or Fisher exact test for categorical data and Mann-Whitney *U* test for quantitative data. Logistic regressions were applied to any significant values for multivariate analysis. A stratified Cox proportional hazards model was used to generate the odds ratio (OR) and 95% confidence interval (CI). The software used to obtain all the analytical values was SPSS for Mac version 20.

Results {#section9-1179546817747258}
=======

Baseline characteristics {#section10-1179546817747258}
------------------------

Between February 2014 and December 2014, the study enrolled 78 patients with CML with 156 control population as the planned 1:2 ratio. In our center, imatinib was first-line treatment of patients with CML. Nilotinib will be provided for imatinib failure or intolerance---so-called "second-line." Dasatinib switching is only for third-line treatment in previous failure or intolerance of nilotinib users. In all, 61 patients (78.2%) were on imatinib (all first line), 13 patients (16.7%) were on nilotinib (all second line), and 4 patients (5.1%) were on dasatinib (all third line). The median durations of the imatinib, nilotinib, and dasatinib treatments were 89.6, 46.7, and 22.1 months, respectively. Seventy-five patients (96.2%) were in the chronic phase of CML. Atherosclerotic risks included hypertension (20.5%), diabetes (12.8%), dyslipidemia (26.9%), metabolic syndrome (19.2%), and smoking (2.6%). The clinical variables and the PAOD-related risk factors are provided in [Table 1](#table1-1179546817747258){ref-type="table"}. All the baseline characteristics were balanced between the TKI groups except that total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were prominent in the nilotinib and the dasatinib users compared with the imatinib users. For control population was matched with patients with CML by age, sex, and diabetes. This group had atherosclerotic risks including hypertension (21.8%), diabetes (12.8%), dyslipidemia (25.0%), and no smoking.

###### 

Clinical variables and PAOD-related risk factors in patients with CML.

![](10.1177_1179546817747258-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                             Case, total\       IM\                NIL\               DAS\               *P* value
                                        n = 78 (%)         n = 61 (%)         n = 13 (%)         n = 4 (%)          
  ------------------------------------- ------------------ ------------------ ------------------ ------------------ -------------------------------------------------------------
  Age, y, median (range)                55 (21-86)         54 (21-83)         68 (25-86)         60 (52-81)         .053

  Male gender                           41 (52.6)          33 (54.1)          6 (46.2)           2 (50)             .868

  BMI, kg/m^2^, median (range)          22.8 (14.4-31.3)   23.4 (17.3-31.3)   22.2 (14.4-28.8)   21.0 (19.5-25.5)   .218

  Previous medical illness                                                                                          

   Hypertension                         16 (20.5)          13 (21.3)          3 (23.1)           ---                .888^[a](#table-fn2-1179546817747258){ref-type="table-fn"}^

   Diabetes mellitus                    10 (12.8)          7 (11.5)           3 (23.1)           ---                .267^[a](#table-fn2-1179546817747258){ref-type="table-fn"}^

   Dyslipidemia                         21 (26.9)          13 (21.3)          6 (46.2)           2 (50)             .108

  Concurrent medications                                                                                            

   Antihypertensive                     9 (11.5)           8 (13.1)           1 (7.7)            ---                .587^[a](#table-fn2-1179546817747258){ref-type="table-fn"}^

   Antiplatelet                         2 (2.6)            2 (3.3)            ---                ---                ---

   Lipid-lowering agents                4 (5.1)            3 (4.9)            1 (7.7)            ---                .688^[a](#table-fn2-1179546817747258){ref-type="table-fn"}^

  Blood chemistry, median                                                                                           

   FPG, mg/dL                           96 (77-222)        95 (80-165)        90 (77-222)        100 (98-111)       .475

   HbA~1C~, g/dL                        5.5 (4.2-10.5)     5.4 (4.2-9.4)      5.7 (4.6-10.5)     5.4 (4.7-5.8)      .133

   Triglycerides, mg/dL                 107 (39-2371)      105 (39-2371)      124 (56-228)       130.5 (79-273)     .752

   Total cholesterol, mg/dL             166 (81-318)       154 (81-297)       206 (137-318)      223 (217-230)      \<.001

   LDL-C, mg/dL                         99.5 (25-233)      92 (25-185)        135 (80-233)       157.5 (152-168)    \<.001

   HDL-C, mg/dL                         51 (23-92)         51 (23-92)         58 (47-91)         48 (31-56)         .037

  Metabolic syndrome                    15 (19.2)          12 (19.7)          2 (15.4)           1 (25)             .897

  Duration of TKI, mo, median (range)   80 (3-233)         89.6 (1.9-194)     46.7 (2.9-67)      22.1 (4.7-45.3)    \<.001

  Line of treatment                                                                                                 \<.001

   First line                           61 (78.2)          61 (100)           ---                ---                

   Second line                          13 (16.7)          ---                13 (100)           ---                

   Third line                           4 (5.1)            ---                ---                4 (100)            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMI, body mass index; CML, chronic myeloid leukemia; DAS, dasatinib; FPG, fasting plasma glucose; HbA~1C~, hemoglobin A~1C~; HDL-C, high-density lipoprotein cholesterol; IM, imatinib; LDL-C, low-density lipoprotein cholesterol; NIL, nilotinib; PAOD, peripheral artery occlusive disease; TKI, tyrosine kinase inhibitor.

When comparing only the IM group with the NIL group.

PAOD in patients with CML {#section11-1179546817747258}
-------------------------

There were 7 patients showing prevalence of 9.0% with pathologic ABI ([Table 2](#table2-1179546817747258){ref-type="table"}, [Figure 1](#fig1-1179546817747258){ref-type="fig"}). Patients receiving nilotinib had the highest prevalence of abnormal ABI of 30.8%, whereas patients receiving imatinib and dasatinib had prevalence of 4.9% and 0%, respectively. Nilotinib-using patients had augmented risk of PAOD, according to the ABI screening, compared with imatinib (OR: 8.59; 95% CI: 1.64-44.89; *P* = .004). For the multivariate analysis, there was only the independent factor of hemoglobin A~1C~ (HbA~1C~) over 7 g/dL (OR: 2.41; 95% CI: 1.11-5.25; *P* = .026) which was positively associated with low ABI. All the 7 patients were asymptomatic and also achieved major molecular response (MR^3.0^) by real-time quantitative polymerase chain reaction. The median age was 70 (50-86) years. Four were used to nilotinib usage with a median duration of 62 (55-67) months. Vascular imaging was performed, but only 2 patients who received nilotinib had significant stenosis of lower limb arteries ([Table 1S](http://journals.sagepub.com/doi/suppl/10.1177/1179546817747258)). Because all of the patients did not have limb ischemia clinically, the vascular surgeons settled on conservative methods with atherosclerosis risk factor modification and closed monitoring.

###### 

Seven cases of CML with pathologic ABI (\<0.9).

![](10.1177_1179546817747258-table2)

  Subject^[a](#table-fn5-1179546817747258){ref-type="table-fn"}^   Vascular imaging                                                                      Gender/age   DM/HT/DLP   TKIs, mg/d, duration
  ---------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------ ----------- ----------------------
  006                                                              CTA: normal                                                                           F/50         −/−/−       IM-400, 116 mo
  035                                                              Ultrasound Doppler: normal                                                            M/59         +/+/−       IM-400, 119 mo
  072                                                              Ultrasound Doppler: normal                                                            M/58         −/+/+       IM-400, 42 mo
  012                                                              Ultrasound Doppler: positive^[b](#table-fn6-1179546817747258){ref-type="table-fn"}^   F/73         −/+/+       NIL-800, 62 mo
  043                                                              CTA: positive^[b](#table-fn6-1179546817747258){ref-type="table-fn"}^                  M/86         −/−/−       NIL-800, 67 mo
  010                                                              Ultrasound Doppler: normal                                                            F/55         −/−/+       NIL-800, 55 mo
  091                                                              Ultrasound Doppler: normal                                                            M/70         +/−/−       NIL-800, 62 mo

Abbreviations: CML, chronic myeloid leukemia; CTA, computed tomography angiography; DLP, dyslipidemia; DM, diabetes mellitus; F, female; HT, hypertension; IM, imatinib; M, male; NIL, nilotinib; TKIs, tyrosine kinase inhibitors.

− indicates nondiagnosed; + indicates diagnosed.

All subjects were asymptomatic and MMR (major molecular response, MR^3.0^ by real-time quantitative polymerase chain reaction method).

Occlusion or significant stenosis of lower leg arteries.

![Peripheral artery occlusive disease prevalence in patients with chronic myeloid leukemia, n = 78. ABI indicates ankle-brachial index.](10.1177_1179546817747258-fig1){#fig1-1179546817747258}

PAOD prevalence compared with control population {#section12-1179546817747258}
------------------------------------------------

Age, sex, and diabetes status of the control population were well matched with the patients with CML, but the control group had higher LDL-C and lower HDL-C levels ([Table 3](#table3-1179546817747258){ref-type="table"}, [Figure 2](#fig2-1179546817747258){ref-type="fig"}). However, the patients with CML, eventually, were found to have more prevalence of PAOD with OR of 2.09 (95% CI: 0.71-6.21; *P* = .181) by ABI.

###### 

Peripheral artery occlusive disease prevalence compared with control population^[a](#table-fn8-1179546817747258){ref-type="table-fn"}^.

![](10.1177_1179546817747258-table3)

  Data                     Case (n = 78)      Control (n = 156)   *P* value
  ------------------------ ------------------ ------------------- -----------
  Age, y                   55 (21-86)         54 (21-83)          .342
  Male gender              52.6               52.6                1.000
  BMI, kg/m^2^             22.8 (14.4-31.3)   23.7 (15.4-40.4)    .085
  Previous illness                                                
   Hypertension            20.5               21.8                .822
   Diabetes mellitus       12.8               12.8                1.000
   Dyslipidemia            26.9               25.0                .751
  Blood chemistry, mg/dL                                          
   FPG                     96 (76-222)        99 (79-231)         .249
   Triglycerides           107 (39-2371)      108 (37-603)        .835
   Total cholesterol       166 (81-318)       204 (51-363)        .178
   LDL-C                   99.5 (25-233)      138 (56-289)        .018
   HDL-C                   51 (23-92)         48 (17-92)          .014

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Values are expressed as median (range) or percentages.

![Comparison of PAOD prevalence between cases of chronic myeloid leukemia and the control group. ABI indicates ankle-brachial index; PAOD, peripheral artery occlusive disease.](10.1177_1179546817747258-fig2){#fig2-1179546817747258}

Discussion {#section13-1179546817747258}
==========

This study was the first to report prevalence of PAOD in patients with CML in Thailand, which was 9% by ABI. The gold standard of PAOD detection is the use of angiogram; however, that method is invasive, carries the risk of contrast-induced nephropathy, and might be exposed to anaphylactoid reaction with infusional contrast media. Less invasive procedures have been invented in various methods, with one of the most generally used being ABI. Peripheral artery occlusive disease screening by ABI has given values lower than 0.9, with sensitivity in the range of 15% to 79%, specificity in the range of 83.3% to 99%, and accuracy in the range of 72.1% to 89.2%.^[@bibr9-1179546817747258]^ The prevalence of PAOD in this study was less than that reported by previous reports which predominantly measured the same by ABI, and the average was 20%. This might be explained by the difference in ethnicities, body mass indexes, cardiovascular risk factors, and numbers of populations in the various studies. For the risk of PAOD among 3 kinds of TKIs, nilotinib uncovered an OR of 8.59 (95% CI: 1.64-44.89; *P* = .004) which harmoniously correlates to the findings of previous studies which reported about 10.3-fold to 14.6-fold higher risk of PAOD in the case of nilotinib compared with imatinib.^[@bibr13-1179546817747258]^ Recently, a review of PAOD screening in patients using only nilotinib showed abnormal ABI or pulse wave velocity in 19.3%,^[@bibr14-1179546817747258]^ which strongly implicates nilotinib therapy as being proatherogenic. Moreover, results of pathologic ABI have reported up to 3.2-fold increase in cardiovascular morbidities in type 2 diabetes,^[@bibr15-1179546817747258]^ and we also found that the only independent risk for PAOD was HbA~1C~ being more than 7 g/dL (OR: 2.41; 95% CI: 1.11-5.25; *P* = .026). This finding reveals the close relationship between PAOD and diabetes mellitus, too. Some of the previous reports of PAOD in CML in comparison with this study are presented in [Table 4](#table4-1179546817747258){ref-type="table"}.

###### 

Previous reports on PAOD in CML.

![](10.1177_1179546817747258-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trials                                    Study design                                          Results
  ----------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------
  Giles et al^[@bibr10-1179546817747258]^   Retrospective\                                        NIL vs IM (OR: 14.5, 95% CI: 2.7-145.6)\
                                            IM = 1301, NIL = 556, no TKIs = 533\                  NIL vs no TKIs (OR: 0.9, 95% CI: 0.2-5.4)\
                                            Clinically overt PAOD, n = 12\                        IM vs no TKIs (OR: 0.06, 95% CI: 0.005-0.5)\
                                            (IM = 2, NIL = 7, no TKIs = 3)                        Conclusion: NIL increased PAOD risk, and IM might be a protective factor

  Kim et al^[@bibr11-1179546817747258]^     Prospective cohort\                                   NIL vs IM (OR: 10.3, 95% CI: 2.3-61.5)\
                                            IM = 54, NIL = 66\                                    NIL arm had older-age patients, more dyslipidemia\
                                            Clinically overt PAOD, n = 24\                        Conclusion: NIL increased PAOD risk
                                            (IM = 3, NIL = 17)                                    

  Lee et al^[@bibr14-1179546817747258]^     Retrospective\                                        Pathologic ABI (\<0.9) = 1/17 (6%)\
                                            NIL = 88\                                             Pathologic arterial stiffness by PWV (1200-2000 cm/s adjusted by age) = 8/17 (47%)
                                            Abnormal ABI or PWV, n = 17\                          
                                            (Cutoff level of ABI \<1.0)                           

  This study                                Cross-sectional case-control PAOD screening by ABI\   NIL vs IM (OR: 8.59; 95% CI: 1.6-44.9)\
                                            n = 78 (case), n = 156 (control)\                     Diabetes mellitus increased risk of PAOD\
                                            IM = 61, NIL = 13, DAS = 4\                           Trend of more PAOD prevalence in CML cases
                                            All were asymptomatic PAOD, n = 7 (IM = 3, NIL = 4)   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; CML, chronic myeloid leukemia; DAS, dasatinib; IM, imatinib; NIL, nilotinib; OR, odds ratio; PAOD, peripheral artery occlusive disease; PWV, pulse wave velocity; TKIs, tyrosine kinase inhibitors.

With reference to earlier PAOD screening development, stiffness of vasculature was the one of the interests. The arterial stiffness usually appears before vascular obstruction. This is because the inflammatory process causes intima media degradation, increase in collagen, calcification, and proteolytic enzymes, resulting in elastin damage and arterial occlusion.^[@bibr16-1179546817747258]^ However, the method of measuring arterial stiffness is not widely used because of inconclusive data for cutoff level and the procedure not being available in most of the centers in our country.

The effect of protein kinase inhibition on endothelium and myocardium has been studied in patients with metastatic renal cell carcinoma who used sunitinib and sorafenib as TKIs for the therapeutic scheme. These studies showed evidence of vasculopathies with circulatory disturbance.^[@bibr17-1179546817747258][@bibr18-1179546817747258]--[@bibr19-1179546817747258]^ As far as nilotinib is concerned, it not only inhibited KIT kinase and PDGFR kinase, which are actions similar to imatinib, but also inhibited the discoidin domain receptor 1 (DDR1) which resulted in plaque formation and atherosclerosis in mouse models.^[@bibr20-1179546817747258]^ The cellular mechanism of DDR1 inhibition also enhanced the possibility of diabetes mellitus with evidence of elevated serum amylase and beta cells indicative of dysfunction of the pancreas.^[@bibr21-1179546817747258]^ Nilotinib may exert proatherogenic and antiangiogenic effects on endothelial cells. Arterial stenosis resulting from the proatherogenesis and the antiangiogenesis of the drug may inhibit the repair mechanism of recanalization and reperfusion.^[@bibr22-1179546817747258]^ Recently, a review on vascular adverse events (VAEs) in TKI-treated patients with CML also reported the frequency of VAEs in nilotinib users as being in the range of 1% to 29%, including PAOD in 1% to 20%, and it also found the number of patients developing VAEs increasing over time.^[@bibr23-1179546817747258]^

To the best of our knowledge, this study was the first case-matched control design study on PAOD risk factor assessment in CML. Interestingly, matched control of age and diabetes had greater LDL-C and lower HDL-C levels, and the PAOD prevalence in CML individuals appeared to be higher for ABI among various kinds of TKIs patients with in CML. Hypercholesterolemia might not be a PAOD predictive risk, or TKIs may play a greater role in vascular inflammation than higher levels of cholesterol in circulation. However, the type of TKI was not found to have an influence on PAOD risk when analyzed using multivariate analysis.

Limitations {#section14-1179546817747258}
-----------

This was a cross-sectional case-control, single-institution study that had a small sample size. Because of the limited resources and reimbursement issues in our center, imatinib was the only first choice for therapy in patients with chronic phase CML, with the second line of treatment and the third line of treatment being scheduled on nilotinib and dasatinib, respectively. There was inequality in the number of patients between the 3 kinds of TKIs, which might have caused misleading in the interpretation of results. This trial was not analysed on sex and aged effects causing PAOD, menopause or andropause might be related factors, number of subjects was inadequate power. Larger number of subjects should be provided to address these outcomes.

Conclusions {#section15-1179546817747258}
===========

The investigation regarding prevalence of PAOD using ABI found that it was higher among patients with CML than in the control population. Patients with CML receiving TKIs and who had diabetes have a higher chance of developing PAOD and should be carefully monitored for this complication. Peripheral artery occlusive disease screening might be made pretreatment schema for patients with CML who have levels of HbA~1C~ higher than 7 g/dL, especially in cases where nilotinib is planned to be included in the long-term treatment.
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